Question for the board, especially Kelt: the other board is getting excited because they think that the continuation of patients in the original cohort is indicative of efficacy. My recollection was that all patients were going to be continued UNLESS adverse side effects were noticed. (In other words, this is still just according to plan and is not a data point.)

Am I remembering incorrectly, or does someone have a press release or email from Leo that talks about this?